These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. (Aryloxy)alkylamines as selective human dopamine D4 receptor antagonists: potential antipsychotic agents. Unangst PC, Capiris T, Connor DT, Doubleday R, Heffner TG, MacKenzie RG, Miller SR, Pugsley TA, Wise LD. J Med Chem; 1997 Dec 05; 40(25):4026-9. PubMed ID: 9406594 [Abstract] [Full Text] [Related]
3. Design, synthesis, and evaluation of chromen-2-ones as potent and selective human dopamine D4 antagonists. Kesten SR, Heffner TG, Johnson SJ, Pugsley TA, Wright JL, Wise LD. J Med Chem; 1999 Sep 09; 42(18):3718-25. PubMed ID: 10479303 [Abstract] [Full Text] [Related]
4. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds. Ohmori J, Maeno K, Hidaka K, Nakato K, Matsumoto M, Tada S, Hattori H, Sakamoto S, Tsukamoto S, Usuda S, Mase T. J Med Chem; 1996 Jul 05; 39(14):2764-72. PubMed ID: 8709107 [Abstract] [Full Text] [Related]
5. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH. J Med Chem; 2005 Feb 10; 48(3):839-48. PubMed ID: 15689168 [Abstract] [Full Text] [Related]
6. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride. Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP, Peglion JL. J Pharmacol Exp Ther; 1998 Oct 10; 287(1):167-86. PubMed ID: 9765336 [Abstract] [Full Text] [Related]
7. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. Patel S, Freedman S, Chapman KL, Emms F, Fletcher AE, Knowles M, Marwood R, Mcallister G, Myers J, Curtis N, Kulagowski JJ, Leeson PD, Ridgill M, Graham M, Matheson S, Rathbone D, Watt AP, Bristow LJ, Rupniak NM, Baskin E, Lynch JJ, Ragan CI. J Pharmacol Exp Ther; 1997 Nov 10; 283(2):636-47. PubMed ID: 9353380 [Abstract] [Full Text] [Related]
8. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. Tallman JF, Primus RJ, Brodbeck R, Cornfield L, Meade R, Woodruff K, Ross P, Thurkauf A, Gallager DW. J Pharmacol Exp Ther; 1997 Aug 10; 282(2):1011-9. PubMed ID: 9262370 [Abstract] [Full Text] [Related]
19. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Glennon JC, Van Scharrenburg G, Ronken E, Hesselink MB, Reinders JH, Van Der Neut M, Long SK, Feenstra RW, McCreary AC. Synapse; 2006 Dec 15; 60(8):599-608. PubMed ID: 17001660 [Abstract] [Full Text] [Related]